[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:alk-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ALK Gene",31,28,[8,16,23,29,35,41,48,54,60,66,72,78,84,91,97,103,109,116,122,128,133,139,145,151,157,163,169,174,180,187,194],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05142189","Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:16:32.589113Z","2026-07-24T01:27:14.869513Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",[20],"Phase 2","2026-08-26T02:16:08.402952Z","2026-06-16T05:54:07.906610Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07013565","Chemoimmunotherapy for ALK+ Relapsed\u002FRefractory ALCL",[20],"2026-08-26T02:15:42.447052Z","2026-05-29T15:36:40.177956Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05828069","A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis",[20],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:29.729634Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06616623","Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.199244Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06333899","Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion",[45],"Early Phase 1","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:29.136961Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04693468","Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",[12],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:28.961863Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05456256","A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",[20],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:28.856420Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06736379","Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer",[12],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.548931Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07405190","Ivonescimab Alone And With Carboplatin\u002FPemetrexed For NSCLC",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.115654Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07415005","Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer",[20],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:28.001047Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[12],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.992106Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":89,"content_modified":90},"NCT04774718","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors",[88],"Phase 1\u002FPhase 2","2026-08-03T02:37:43.197556Z","2026-05-05T02:43:27.965421Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05950139","Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC",[88],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:27.927736Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06007937","A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer",[88],"2026-08-03T02:04:08.415522Z","2026-05-05T02:43:27.674879Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer",[20],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.103317Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":114,"content_modified":115},"NCT06765109","Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC",[113],"Phase 3","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:27.054944Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05987644","Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements",[88],"2026-08-26T02:16:40.941792Z","2026-04-29T02:57:57.103134Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[88],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":46,"content_modified":132},"NCT05004116","A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer",[88],"2026-05-05T02:43:27.261412Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[12],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT03093116","A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",[88],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.489051Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[20],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[88],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT05024929","Targeted Therapy to Increase RAI Uptake in Metastatic DTC",[],"2026-08-26T02:15:44.309045Z","2026-05-13T02:55:06.280918Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT03042221","Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy",[],"2026-08-26T02:17:27.435233Z","2026-05-13T02:55:06.106741Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":161,"content_modified":173},"NCT04900935","Patient-centered, Optimal Integration of Survivorship and Palliative Care",[],"2026-05-05T02:43:28.871702Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT04151940","PET\u002FCT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer",[],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.577751Z",{"nct_id":181,"title":182,"phases":183,"status":184,"updated_at":185,"content_modified":186},"NCT06943664","Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer",[20],"NOT_YET_RECRUITING","2026-08-26T02:18:51.833592Z","2026-04-29T02:57:57.162640Z",{"nct_id":188,"title":189,"phases":190,"status":191,"updated_at":192,"content_modified":193},"NCT03922724","Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:45:11.273644Z","2026-05-05T02:43:28.670136Z",{"nct_id":195,"title":196,"phases":197,"status":191,"updated_at":198,"content_modified":199},"NCT06074588","Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",[113],"2026-08-03T02:08:28.425355Z","2026-05-05T02:35:31.905794Z"]